HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

An important hallmark of CRC is the evasion of immune surveillance. HLA-G is a negative regulator of host's immune response. Overexpression of HLA-G protein in primary tumour CRC tissues has already been associated to worse prognosis; however a definition of the role of immunogenetic host backg...

Full description

Bibliographic Details
Main Authors: Marica Garziera, Ettore Bidoli, Erika Cecchin, Enrico Mini, Stefania Nobili, Sara Lonardi, Angela Buonadonna, Domenico Errante, Nicoletta Pella, Mario D'Andrea, Francesco De Marchi, Antonino De Paoli, Chiara Zanusso, Elena De Mattia, Renato Tassi, Giuseppe Toffoli
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4669157?pdf=render
id doaj-6727e3b8b32c4fa2b74573e56787b119
record_format Article
spelling doaj-6727e3b8b32c4fa2b74573e56787b1192020-11-24T21:36:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014400010.1371/journal.pone.0144000HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.Marica GarzieraEttore BidoliErika CecchinEnrico MiniStefania NobiliSara LonardiAngela BuonadonnaDomenico ErranteNicoletta PellaMario D'AndreaFrancesco De MarchiAntonino De PaoliChiara ZanussoElena De MattiaRenato TassiGiuseppe ToffoliAn important hallmark of CRC is the evasion of immune surveillance. HLA-G is a negative regulator of host's immune response. Overexpression of HLA-G protein in primary tumour CRC tissues has already been associated to worse prognosis; however a definition of the role of immunogenetic host background is still lacking. Germline polymorphisms in the 3'UTR region of HLA-G influence the magnitude of the protein by modulating HLA-G mRNA stability. Soluble HLA-G has been associated to 3'UTR +2960 Ins/Ins and +3035 C/T (lower levels) and +3187 G/G (high levels) genotypes. HLA-G 3'UTR SNPs have never been explored in CRC outcome. The purpose of this study was to investigate if common HLA-G 3'UTR polymorphisms have an impact on DFS and OS of 253 stage II-III CRC patients, after primary surgery and ADJ-CT based on FL. The 3'UTR was sequenced and SNPs were analyzed for their association with survival by Kaplan-Meier and multivariate Cox models; results underwent internal validation using a resampling method (bootstrap analysis). In a multivariate analysis, we estimated an association with improved DFS in Ins allele (Ins/Del +Ins/Ins) carriers (HR 0.60, 95% CI 0.38-0.93, P = 0.023) and in patients with +3035 C/T genotype (HR 0.51, 95% CI 0.26-0.99, P = 0.045). The +3187 G/G mutated carriers (G/G vs A/A+A/G) were associated to a worst prognosis in both DFS (HR 2.46, 95% CI 1.19-5.05, P = 0.015) and OS (HR 2.71, 95% CI 1.16-6.63, P = 0.022). Our study shows a prognostic and independent role of 3 HLA-G 3'UTR SNPs, +2960 14-bp INDEL, +3035 C>T, and +3187 A>G.http://europepmc.org/articles/PMC4669157?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Marica Garziera
Ettore Bidoli
Erika Cecchin
Enrico Mini
Stefania Nobili
Sara Lonardi
Angela Buonadonna
Domenico Errante
Nicoletta Pella
Mario D'Andrea
Francesco De Marchi
Antonino De Paoli
Chiara Zanusso
Elena De Mattia
Renato Tassi
Giuseppe Toffoli
spellingShingle Marica Garziera
Ettore Bidoli
Erika Cecchin
Enrico Mini
Stefania Nobili
Sara Lonardi
Angela Buonadonna
Domenico Errante
Nicoletta Pella
Mario D'Andrea
Francesco De Marchi
Antonino De Paoli
Chiara Zanusso
Elena De Mattia
Renato Tassi
Giuseppe Toffoli
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
PLoS ONE
author_facet Marica Garziera
Ettore Bidoli
Erika Cecchin
Enrico Mini
Stefania Nobili
Sara Lonardi
Angela Buonadonna
Domenico Errante
Nicoletta Pella
Mario D'Andrea
Francesco De Marchi
Antonino De Paoli
Chiara Zanusso
Elena De Mattia
Renato Tassi
Giuseppe Toffoli
author_sort Marica Garziera
title HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
title_short HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
title_full HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
title_fullStr HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
title_full_unstemmed HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
title_sort hla-g 3'utr polymorphisms impact the prognosis of stage ii-iii crc patients in fluoropyrimidine-based treatment.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description An important hallmark of CRC is the evasion of immune surveillance. HLA-G is a negative regulator of host's immune response. Overexpression of HLA-G protein in primary tumour CRC tissues has already been associated to worse prognosis; however a definition of the role of immunogenetic host background is still lacking. Germline polymorphisms in the 3'UTR region of HLA-G influence the magnitude of the protein by modulating HLA-G mRNA stability. Soluble HLA-G has been associated to 3'UTR +2960 Ins/Ins and +3035 C/T (lower levels) and +3187 G/G (high levels) genotypes. HLA-G 3'UTR SNPs have never been explored in CRC outcome. The purpose of this study was to investigate if common HLA-G 3'UTR polymorphisms have an impact on DFS and OS of 253 stage II-III CRC patients, after primary surgery and ADJ-CT based on FL. The 3'UTR was sequenced and SNPs were analyzed for their association with survival by Kaplan-Meier and multivariate Cox models; results underwent internal validation using a resampling method (bootstrap analysis). In a multivariate analysis, we estimated an association with improved DFS in Ins allele (Ins/Del +Ins/Ins) carriers (HR 0.60, 95% CI 0.38-0.93, P = 0.023) and in patients with +3035 C/T genotype (HR 0.51, 95% CI 0.26-0.99, P = 0.045). The +3187 G/G mutated carriers (G/G vs A/A+A/G) were associated to a worst prognosis in both DFS (HR 2.46, 95% CI 1.19-5.05, P = 0.015) and OS (HR 2.71, 95% CI 1.16-6.63, P = 0.022). Our study shows a prognostic and independent role of 3 HLA-G 3'UTR SNPs, +2960 14-bp INDEL, +3035 C>T, and +3187 A>G.
url http://europepmc.org/articles/PMC4669157?pdf=render
work_keys_str_mv AT maricagarziera hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT ettorebidoli hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT erikacecchin hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT enricomini hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT stefanianobili hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT saralonardi hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT angelabuonadonna hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT domenicoerrante hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT nicolettapella hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT mariodandrea hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT francescodemarchi hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT antoninodepaoli hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT chiarazanusso hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT elenademattia hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT renatotassi hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
AT giuseppetoffoli hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment
_version_ 1725939833730236416